Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
Suliman Al-Fayoumi,1 Taishi Hashiguchi,2 Yuka Shirakata,2 John Mascarenhas,3 Jack W Singer1 1CTI BioPharma, Seattle, WA, USA; 2SMC Laboratories, Tokyo, Japan; 3Tish Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Background: Fibrotic diseases result from an exuberant res...
Main Authors: | Al-Fayoumi S, Hashiguchi T, Shirakata Y, Mascarenhas J, Singer JW |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-05-01
|
Series: | Journal of Experimental Pharmacology |
Subjects: | |
Online Access: | https://www.dovepress.com/pilot-study-of-the-antifibrotic-effects-of-the-multikinase-inhibitor-p-peer-reviewed-fulltext-article-JEP |
Similar Items
-
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
by: Singer J, et al.
Published: (2016-08-01) -
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
by: Srdan Verstovsek, et al.
Published: (2016-12-01) -
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
by: Srdan Verstovsek, et al.
Published: (2017-02-01) -
Assessment of interleukin-10 level and Janus kinase 2 V617F mutation incidence in patients with primary myelofibrosis
by: Shahla′a Fadhil Sabir
Published: (2016-01-01) -
Primary myelofibrosis: current therapeutic options
by: Paula de Melo Campos